As known candidates for targeted treatment, molecular inhibitors such as MEK inhibitor and mTOR inhibitor have been used for some types of vascular malformations, because most vascular malformations are caused by genetic mutations that lead to the hyperactivity of RAS/MAPK/ERK or PI3K/AKT/mTOR pathways [9]. The gene discussed is MAP2K7; the disease is vascular malformation.